GeneQuantum Healthcare develops innovative bioconjugate drugs, focusing on antibody-drug conjugates (ADCs), via an enzyme-catalyzed intelligent continuous conjugation platform. The platform has achieved pilot production for next-generation highly homogeneous ADCs with improved quality and reduced costs and advances existing chemical conjugation production modes. The process can be widely applied to the automated manufacturing of various bioconjugate drugs represented by ADCs. GeneQuantum has established cooperation with pharmaceutical companies on innovative bioconjugate drug research and development. The company intends to use the financing to promote global clinical development of next-generation ADCs and to rapidly develop and deploy a series of differentiated innovative technologies and products. The company is led by Dr. Gang Qin and is based in Suzhou, China. GeneQuantum Healthcare, founded in August 2013 in Suzhou Industrial Park by Dr. Gang Qin (CEO), focuses on R&D of innovative biotherapeutics. The company has built a bio-conjugation technology platform and is developing a series of anti-tumor ADC candidates. It completed an RMB40m (approx. $5.8m) Series A financing to support those programs. GeneQuantum intends to use the funds to advance current ADC candidates toward IND filing in both the US and China. The company also plans to further expand its product pipeline using the proceeds. The description above reflects the company's stated near-term development and financing status.

Total raised

$21M

Funding rounds

2

Latest round

Series B

Latest activity

May 2019